Literature DB >> 19329550

Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats.

G D Cooper1, A J Goudie, J C G Halford.   

Abstract

Olanzapine is a novel antipsychotic drug known to induce clinically significant weight gain. Although the cause of such weight gain is not fully known, drug-induced changes in appetite and food intake are likely to play a significant role together with other possible mechanisms enhancing weight and/or adiposity. We assessed acute drug effects on 1 hour intake and behavioural expression in female rats. Low doses of olanzapine (0.5 and 1 mg/kg) enhanced acute mash intake. Marked drug effects were seen on a number of behaviours following olanzapine over a range of doses. These effects included dose-related reductions in activity and exploratory behaviours and associated substantial dose-related increases in resting behaviour. Behavioural data were also used to plot drug effects over time, including behavioural satiety sequence (BSS) profiles, to evaluate whether olanzapine's hyperphagic effects might be a consequence of altered satiety development. BSS profiles reflected enhanced eating behaviour at low doses (0.5 and 1 mg/kg) but showed dose-related increases in resting, indicative of drug-induced sedation, which meant that it was impossible to fully discern olanzapine's effects on satiety. Acute olanzapine induces both hyperphagia and sedation, both of which may promote weight gain and adiposity, but which interact competitively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329550     DOI: 10.1177/0269881109102543

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  7 in total

1.  Effects of the cannabinoid-1 receptor antagonist/inverse agonist rimonabant on satiety signaling in overweight people with schizophrenia: a randomized, double-blind, pilot study.

Authors:  Kimberly R Warren; Robert W Buchanan; Stephanie Feldman; Robert R Conley; Jared Linthicum; Mary Patricia Ball; Fang Liu; Robert P McMahon; David A Gorelick; Marilyn A Huestis; Deanna L Kelly
Journal:  J Clin Psychopharmacol       Date:  2013-02       Impact factor: 3.153

2.  Early perturbation in feeding behaviour and energy homeostasy in olanzapine-treated rats.

Authors:  Montserrat Victoriano; Dominique Hermier; Patrick C Even; Gilles Fromentin; Jean-François Huneau; Daniel Tomé; Renaud de Beaurepaire
Journal:  Psychopharmacology (Berl)       Date:  2009-07-02       Impact factor: 4.530

Review 3.  Atypical antipsychotics and effects on feeding: from mice to men.

Authors:  Louise Benarroch; Chantel Kowalchuk; Virginia Wilson; Celine Teo; Melanie Guenette; Araba Chintoh; Yasika Nesarajah; Valerie Taylor; Peter Selby; Paul Fletcher; Gary J Remington; Margaret K Hahn
Journal:  Psychopharmacology (Berl)       Date:  2016-06-01       Impact factor: 4.530

4.  The potential role of appetite in predicting weight changes during treatment with olanzapine.

Authors:  Michael Case; Tamas Treuer; Jamie Karagianis; Vicki Poole Hoffmann
Journal:  BMC Psychiatry       Date:  2010-09-14       Impact factor: 3.630

5.  A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.

Authors:  Vance L Albaugh; Ravi Singareddy; David Mauger; Christopher J Lynch
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

6.  A comparison of the nutrient intake of a community-dwelling first-episode psychosis cohort, aged 19-64 years, with data from the UK population.

Authors:  Kevin Williamson; Karen Kilner; Nicola Clibbens
Journal:  J Nutr Sci       Date:  2015-08-20

7.  Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site.

Authors:  Candice M Klingerman; Michelle E Stipanovic; Andras Hajnal; Christopher J Lynch
Journal:  Dose Response       Date:  2015-11-26       Impact factor: 2.658

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.